Trial intelligence / Profile preview

Danish Pre-HCQ Dialysis Study

2020-001257-51Phase 3Terminated

Sponsor
Rigshospitalet
Start
Mar 2020
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Hospitalization due to SARS-CoV-2 infection. Started Mar 2020; status: terminated.

02

Drugs

hydroxychloroquine
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on 2020-001257-51.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-001257-51.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call